FDA makes MitraClip available to more patients with mitral regurgitation
Since 2013, minimally invasive surgery for mitral valve repair has been available for patients with primary mitral regurgitation who can’t have open heart surgery. The innovative transcatheter MitraClip® device can bring relief to patients without the risk of conventional surgery.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Just five years later, researchers in the COAPT trial reported that MitraClip repair also showed significant benefits for patients with symptomatic mitral regurgitation secondary to heart failure. The transcatheter repair device reduced all-cause mortality and hospitalization compared with medical therapy.
In response, the FDA recently broadened its approval of the device, making minimally invasive repair an option for more people with mitral regurgitation.
In this video, learn more about why expanded use of minimally invasive mitral valve surgery is one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.
Advertisement
Advertisement
Advanced software streamlines charting, supports deeper patient connections
How holding simulations in clinical settings can improve workflow and identify latent operational threats
Interactive Zen Quest experience helps promote relaxing behaviors
Cleveland Clinic and IBM leaders share insights, concerns, optimism about impacts
Cleveland Clinic partners with Palantir to create logistical command center
A Q&A with organizational development researcher Gina Thoebes
Cleveland Clinic transformation leader led development of benchmarking tool with NAHQ
Raed Dweik, MD, on change management and the importance of communication